Close Menu
Congo Tech
    Facebook X (Twitter) Instagram
    Trending
    • Moon Dust Turned Into LEGO-Like Bricks for Lunar Bases
    • Marvell Agrees a $115 Billion Deal to Buy Lumentum in AI Optics Push
    • SpaceX Catches a Falling Rocket With Giant Chopsticks
    • A Blood Test Can Now Help Diagnose Alzheimer’s
    • Two-Nanometre Chips Enter Volume Production
    • Sepsis Kills Millions and Early Recognition Saves Lives
    • Smart Glasses Are Having Their Biggest Year Yet
    • Microplastics Are Now Found Throughout the Human Body
    Facebook X (Twitter) Instagram Pinterest Vimeo
    Congo TechCongo Tech
    • Home
    • Tech News
    • Robotics
    • Mobile App
    • Data Science
    • Software
    Congo Tech
    Home»Blog»A Blood Test Can Now Help Diagnose Alzheimer’s
    Blog

    A Blood Test Can Now Help Diagnose Alzheimer’s

    Jack EvansBy Jack EvansNovember 20, 2026No Comments3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    A nurse drawing a blood sample from a patient's arm.

    Diagnosing Alzheimer’s disease has long meant a spinal tap or an expensive brain scan, procedures that many patients avoid or cannot access. That changed on 16 May 2025, when the United States Food and Drug Administration cleared the first blood test to aid in diagnosing Alzheimer’s. The test, called the Lumipulse G pTau217 and beta-Amyloid 1-42 Plasma Ratio and made by Fujirebio Diagnostics, measures two proteins in a blood sample and calculates their ratio to detect the amyloid plaques that are a hallmark of the disease. It is intended for adults aged 55 and older who already show signs of memory or thinking problems. In the study submitted to the regulator, based on 499 blood samples from cognitively impaired adults, a positive result correctly predicted amyloid pathology 91.7 percent of the time, and a negative result ruled it out 97.3 percent of the time.

    What the Evidence Shows

    The test is a diagnostic aid, not a diagnosis on its own, and doctors must still combine it with a clinical examination and, in some cases, a scan or spinal tap. Fewer than 20 percent of results fall into an indeterminate middle zone that needs further testing, and the price, estimated at 500 to 1,000 dollars, is still high, though far cheaper than a PET brain scan. The timing matters because new Alzheimer’s drugs, lecanemab and donanemab, work best when given early, and they require confirmation of amyloid in the brain before treatment can begin. With more than 55 million people worldwide living with dementia, according to the World Health Organization, a simple blood test taken at a doctor’s surgery could bring diagnosis within reach of far more patients, and far earlier, than the current system allows. Reporting and analysis from sources such as Nature track the same developments, and specialists following Alzheimer’s blood test say the direction is now consistent across independent lines of evidence.

    The Wider Context

    The wider context is a research landscape in which replication and open data now decide reputations. Findings connected to Alzheimer’s blood test are being checked by independent groups with shared datasets, and the teams involved publish their methods in full so rivals can test every step. That discipline is slower than a headline cycle, but it is why results in this area increasingly survive first contact with scrutiny.

    What Happens Next

    What happens next in the story of Alzheimer’s blood test will be decided by follow-up work already under way: larger samples, longer observation and instruments that have not yet come online. The researchers involved are unusually united on one point, that the current results justify the next investment of time and money. Readers will not have to wait long for the first tests of that claim. You can follow related developments in our coverage of science.

    None of this will be settled by a single announcement, study or product launch. The pattern to watch is accumulation: independent confirmations, honest reporting of failures and steady improvement in the underlying numbers. Readers who follow those signals, rather than the loudest claim of the week, will understand this subject better than most of the commentary surrounding it suggests is possible.

    Alzheimer's blood test diagnosis
    Previous ArticleTwo-Nanometre Chips Enter Volume Production
    Next Article SpaceX Catches a Falling Rocket With Giant Chopsticks
    Jack Evans

    Related Posts

    Blog

    Moon Dust Turned Into LEGO-Like Bricks for Lunar Bases

    November 22, 2026
    Blog

    Marvell Agrees a $115 Billion Deal to Buy Lumentum in AI Optics Push

    November 22, 2026
    Blog

    SpaceX Catches a Falling Rocket With Giant Chopsticks

    November 20, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Search
    Recent Posts

    Moon Dust Turned Into LEGO-Like Bricks for Lunar Bases

    November 22, 2026

    Marvell Agrees a $115 Billion Deal to Buy Lumentum in AI Optics Push

    November 22, 2026

    SpaceX Catches a Falling Rocket With Giant Chopsticks

    November 20, 2026

    A Blood Test Can Now Help Diagnose Alzheimer’s

    November 20, 2026

    Two-Nanometre Chips Enter Volume Production

    November 20, 2026

    Sepsis Kills Millions and Early Recognition Saves Lives

    November 20, 2026
    About Us

    Congo Tech drives digital transformation, fuels innovation, boosts business growth across Africa using cutting-edge

    technology solutions – best way to grow, lead, and thrive in the digital age. Empowering enterprises, startups, and communities with smart tech. #CongoTech

    Facebook X (Twitter) Instagram WhatsApp
    Popular Posts

    Moon Dust Turned Into LEGO-Like Bricks for Lunar Bases

    November 22, 2026

    Marvell Agrees a $115 Billion Deal to Buy Lumentum in AI Optics Push

    November 22, 2026

    SpaceX Catches a Falling Rocket With Giant Chopsticks

    November 20, 2026
    Contact Us

    At Congo Tech, we’re always open to hearing from you. Whether it’s a news tip, advertising inquiry, or a support request — don’t hesitate to connect with us.

    Email: contact@outreachmedia .io
    Phone: +92 305 5631208

    Address: 2839 Prudence Street
    Dearborn, MI 48126

    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    • Terms and Conditions
    • Write For Us
    • Sitemap

    Copyright © 2026 | All Right Reserved | Congo Tech

    Type above and press Enter to search. Press Esc to cancel.

    WhatsApp us